Hisamitsu Pharmaceutical Co Inc 2022 IR
The report outlines Hisamitsu Pharmaceutical Group's financial and non-financial performance for the fiscal year ended February 28, 2022. Under its new mission, 'Promoting TE-A-TE Culture Worldwide,' the company launched its Seventh Medium-term Management Policy, HX2025, targeting a 5% CAGR sales growth rate and an 8% ROE by FY2025. Key achievements include a 28.5% reduction in CO2 emissions compared to FY2013, the endorsement of the TCFD recommendations, and the launch of eco-friendly 'Eco & Compact' packaging. Additionally, the company expanded its diversity initiatives, increasing the ratio of female managers to 7.1%.
Company: Hisamitsu Pharmaceutical Co Inc
Sector: Health Care
Country: Japan
Year: 2022
Type: IR
Pages: 31
Hisamitsu Pharmaceutical Co Inc
Integrated Report
The report outlines Hisamitsu Pharmaceutical Group's financial and non-financial performance for the fiscal year ended February 28, 2022. Under its new mission, 'Promoting TE-A-TE Culture Worldwide,' the company launched its Seventh Medium-term Management Policy, HX2025, targeting a 5% CAGR sales growth rate and an 8% ROE by FY2025. Key achievements include a 28.5% reduction in CO2 emissions compared to FY2013, the endorsement of the TCFD recommendations, and the launch of eco-friendly 'Eco & Compact' packaging. Additionally, the company expanded its diversity initiatives, increasing the ratio of female managers to 7.1%.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Mar 1, 2021 - Feb 28, 2022
Fiscal Year
2021
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Women in Management
Net Zero Target
Employees